Citations

Showing 10 of 108094 citations.

EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study
Cupit-Link, Margaret , Rao, Amulya Nageswara, Rodriguez, Vilmarie , Khan, Shakila P. , Nageswara Rao, Amulya, Warad, Deepti M, Khan, Shakila, Rao, Amulya A. Nageswara , Warad, Deepti

Mayo Clinic

Journal of Pediatric Hematology/Oncology | April 4, 2018 | Volume: 40 | Issue: 8 | Pages: e473-e478

10.1097/mph.0000000000001138 | PMID 29620685 Get It

The risk of viral infections and reactivation occurring in the setting of pediatric allogeneic hematopoietic stem cell transplantation is a concern in the pediatric patient, especially with the use of Alemtuzumab (Campath) as a conditioning agent. The purpose of this study was to determine the incidence of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV-PTLD), cytomegalovirus (CMV), and adenovirus among pediatric recipients of alemtuzumab at our institution. We found that EBV-PTLD occurred in 2.1% of transplants (1 matched unrelated donor [MUD] recipient), CMV reactivation occurred in 12.5% of transplants (4 MUD and 2 matched related donor [MRD] recipients) with disseminated CMV in 2.1% of cases (1 MRD recipient), and adenovirus infection occurred in 8.3% of the total transplants (2 MUD and 2 MRD recipients). Alemtuzumab continues to be used as a method of graft-versus-host disease and graft failure prevention among pediatric recipients of hematopoietic stem cell transplantation and seems to be safer than previously reported. At our institution, alemtuzumab has not increased the risk for EBV-PTLD, CMV infection, or adenovirus.
Editorial Comment
Bhindi, Bimal , Wallis, Christopher J D

Mayo Clinic

Journal of Urology | April 4, 2018 | Volume: 200 | Issue: 1 | Pages: 125-125

10.1016/j.juro.2018.03.118 | PMID 29626446 Get It

Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer‐associated venous thromboembolism
Simmons, Benjamin, Wysokiński, Waldemar E. , Saadiq, Rayya A. , Bott‐Kitslaar, Dalene , Casanegra, Ana I. , Lenz, Charles J., Daniels, Paul R. , Bjarnason, Haraldur , Vargas, Emily , Hodge, David O. , Loprinzi, Charles L. , Wysokinski, Waldemar , Casanegra, Ana, Lenz, Charles, Daniels, Paul, Hodge, David, Holton, Sara J, Loprinzi, Charles, McBane, Robert , Casanegra, Ana I , Henkin, Stanislav , Holton, Sara , Cerhan, James R. , McBane, Robert D. , Bjarnason, Haraldur

Mayo Clinic

European Journal of Haematology | April 4, 2018 | Volume: 101 | Issue: 2 | Pages: 136-142

10.1111/ejh.13074 | PMID 29617053 Get It

AbstractBackgroundLow molecular weight heparin (LMWH) is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE.MethodsUsing a cohort study design, consecutive patients with cVTE (3/1/2013‐7/31/2016), enrolled in the Mayo Thrombophilia Clinic Direct Oral Anticoagulants Registry, were compared to contemporary cancer patients receiving enoxaparin. The cumulative incidence of venous thromboembolism (VTE) recurrence, major and clinically relevant non‐major bleeding, and survival were assessed at 3 and 12 months.ResultsNinety‐eight patients received rivaroxaban (51% female, mean age 63 ± 12 years) and 168 enoxaparin (34.5% female, mean age 62 ± 15 years). The most common cancers included gastrointestinal/pancreatic, genitourinary and hematologic cancers. More than half of patients had pulmonary emboli at presentation. More than half had metastases, and two‐thirds were receiving chemotherapy. At 3 months, there were no differences in VTE recurrence (rivaroxaban 1.0% vs enoxaparin 4.2%; P = .15), major bleeding (rivaroxaban 5.1% vs enoxaparin 3.6%; P = .55), or all‐cause mortality (rivaroxaban 4.1% vs enoxaparin 8.9%; P = .14). At 12 months, these outcomes did not differ by treatment strategy.ConclusionThe results of this “real‐world” experience with cVTE suggest that rivaroxaban may offer a safe and effective alternative to LMWH.
Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations
Trabert, Britton , Waterboer, Tim , Idahl, Annika , Brenner, Nicole , Brinton, Louise A. , Butt, Julia , Hartge, Patricia, Hufnagel, Katrin , Inturrisi, Federica , Lissowska, Jolanta , Mentzer, Alexander J. , Pepłońska, Beata , Wills, Gillian, Woodhall, Sarah C , Wentzensen, Nicolas , Trabert, B , Lissowska, Jolanta , Coburn, Sally B. , Sherman, Mark E. , Pawlita, Michael , Mentzer, Alexander J

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 4, 2018 | Volume: 111 | Issue: 2 | Pages: 129-136

10.1093/jnci/djy084 | PMID 29790947 Get It

How Do Elbows Dislocate?
O’Driscoll, Shawn W. , Fitzsimmons, James S

Mayo Clinic

Journal of Bone and Joint Surgery | April 4, 2018 | Volume: 100 | Issue: 7 | Pages: e46

10.2106/jbjs.17.01448 | PMID 29613937 Get It

Comparison of Autograft and Allograft with Surface Modification for Flexor Tendon Reconstruction
Wei, Zhuang, Reisdorf, Ramona L., Thoreson, Andrew R. , Moran, Steven L. , An, Kai‐Nan , Amadio, Peter C. , Zhao, Chunfeng , Wei, Zhuang, Jay, Gregory D.

Mayo Clinic

Journal of Bone and Joint Surgery | April 4, 2018 | Volume: 100 | Issue: 7 | Pages: e42

10.2106/jbjs.17.00925 | PMID 29613931 Get It

Background: Flexor tendon injury is common, and tendon reconstruction is indicated clinically if the primary repair fails or cannot be performed immediately after tendon injury. The purpose of the current study was to compare clinically standard extrasynovial autologous graft (EAG) tendon and intrasynovial allogeneic graft (IAG) that had both undergone biolubricant surface modification in a canine in vivo model. Methods: Twenty-four flexor digitorum profundus (FDP) tendons from the second and fifth digits of 12 dogs were used for this study. In the first phase, a model of failed FDP tendon repair was created. After 6 weeks, the ruptured FDP tendons with a scarred digit were reconstructed with the use of either EAG or IAG tendons treated with carbodiimide-derivatized hyaluronic acid and lubricin. At 12 weeks after tendon reconstruction, the digits were harvested for functional, biomechanical, and histologic evaluations. Results: The tendon failure model was a clinically relevant and reproducible model for tendon reconstruction. The IAG group demonstrated improved digit function with decreased adhesion formation, lower digit work of flexion, and improved graft gliding ability compared with the EAG group. However, the IAG group had decreased healing at the distal tendon-bone junction. Our histologic findings verified the biomechanical evaluations and, further, showed that cellular repopulation of allograft at 12 weeks after reconstruction is still challenging. Conclusions: FDP tendon reconstruction using IAG with surface modification has some beneficial effects for reducing adhesions but demonstrated inferior healing at the distal tendon-bone junction compared with EAG. These mixed results indicate that vitalization and turnover acceleration are crucial to reducing failure of reconstruction with allograft. Clinical Relevance: Flexor tendon reconstruction is a common surgical procedure. However, postoperative adhesion formation may lead to unsatisfactory clinical outcomes. In this study, we developed a potential flexor tendon allograft using chemical and tissue-engineering approaches. This technology could improve function following tendon reconstruction.
Long-Term Outcomes of Glenohumeral Arthrodesis
Wagner, Eric R. , McLaughlin, Richard J. , Sarfani, Shumaila , Cofield, Robert H. , Sperling, John W. , Elhassan, Bassem T. , McLaughlin, Richard, Sanchez-Sotelo, Joaquin, Wagner, Eric R , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Bone and Joint Surgery | April 4, 2018 | Volume: 100 | Issue: 7 | Pages: 598-604

10.2106/jbjs.17.00428 | PMID 29613929 Get It

Background: Glenohumeral arthrodesis is associated with a high rate of complications. Although patients experience reasonable pain relief and shoulder stability, they experience marked limitations in their upper-extremity function. The purpose of this study was to examine the clinical outcomes of glenohumeral arthrodesis. Methods: Twenty-nine patients with 29 affected shoulders underwent primary glenohumeral arthrodesis between 1992 and 2009. Surgical indications included rotator cuff arthropathy and pseudoparalysis (n = 7), neurologic injuries (n = 12), chronic infection (n = 3), recurrent dislocations (n = 3), and proximal humeral or shoulder girdle tumors (n = 4). Surgical fixation techniques included plates and screws in 18 patients and screws only in 11 patients. Results: All patients were examined, with a mean follow-up of 12 years (range, 2 to 22 years). Twelve patients (41%) had postoperative complications, including 6 periprosthetic fractures, 7 nonunions, and 3 infections. Eleven patients (38%) required additional surgical procedures after arthrodesis, including revision internal fixation to achieve glenohumeral fusion after nonunions (n = 7), irrigation and debridement with antibiotic treatment for deep infections (n = 2), open reduction and internal fixation to treat fracture (n = 2), and implant removal to treat symptomatic patients (n = 3). Patients experienced reasonable overall pain relief. The mean postoperative scores were 35 points for the Subjective Shoulder Value, 58 points for the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, and 54 points for the Short Form-36. Eighty-seven percent of patients reported postoperative limitations. Patients with neurologic injuries had worse functional outcomes, and an arthrodesis position of ≥25° yielded better functional outcomes. Conclusions: Glenohumeral arthrodesis is associated with a high rate of patients with complications (41%). Although patients experience reasonable pain relief and shoulder stability, they experience marked limitations in their upper-extremity function. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Clinical Impact of Cabin Altitude Restriction Following Aeromedical Evacuation
Butler, William P., Steinkraus, Lawrence W., Burlingame, Esther, Smith, Danny E., Fouts, Brittany L., Serres, Jennifer L., Burch, David

Mayo Clinic

Military Medicine | April 4, 2018 | Volume: 183 | Issue: suppl_1 | Pages: 193-202

10.1093/milmed/usx171 | PMID 29635577 Get It

Multiple myeloma – a cure within reach
Gertz, Morie A. , Gertz, Morie A

Mayo Clinic

Leukemia & Lymphoma | April 4, 2018 | Volume: 59 | Issue: 11 | Pages: 2521-2523

10.1080/10428194.2018.1452221 | PMID 29616849 Get It

Expression of the B splice variant of NBCe1 (SLC4A4) in the mouse kidney
Fang, Lijuan, Lee, Hyun‐Wook , Chen, Chao , Harris, Autumn N. , Romero, Michael F. , Verlander, Jill W. , Weiner, I. David , Weiner, I David , Romero, Michael F

Mayo Clinic

American Journal of Physiology-Renal Physiology | April 4, 2018 | Volume: 315 | Issue: 3 | Pages: F417-F428

10.1152/ajprenal.00515.2017 | PMID 29631353 Get It

Sodium-coupled bicarbonate transporters are critical for renal electrolyte transport. The electrogenic, sodium-coupled bicarbonate cotransporter, isoform 1 (NBCe1), encoded by the SLC4A4 geneencoded by the SLC4A4 gene has five multiple splice variants; the A splice variant, NBCe1-A, is the primary basolateral bicarbonate transporter in the proximal convoluted tubule. This study’s purpose was to determine if there is expression of additional NBCe1 splice variants in the mouse kidney, their cellular distribution, and their regulation by metabolic acidosis. In wild-type mice, an antibody reactive only to NBCe1-A showed basolateral immunolabel only in cortical proximal tubule (PT) segments, whereas an antibody reactive to all NBCe1 splice variants (pan-NBCe1) showed basolateral immunolabel in PT segments in both the cortex and outer medulla. In mice with NBCe1-A deletion, the pan-NBCe1 antibody showed basolateral PT immunolabel in both the renal cortex and outer stripe of the outer medulla, and immunoblot analysis showed expression of a ~121-kDa protein. RT-PCR of mRNA from NBCe1-A knockout mice directed at splice variant-specific regions showed expression of only NBCe1-B mRNA. In wild-type kidney, RT-PCR confirmed expression of mRNA for the NBCe1-B splice variant and absence of mRNA for the C, D, and E splice variants. Finally, exogenous acid loading increased expression in the proximal straight tubule in the outer stripe of the outer medulla. These studies demonstrate that the NBCe1-B splice variant is present in the PT, and its expression increases in response to exogenous acid loading, suggesting it participates in the PT contribution to acid-base homeostasis.